Документ подписан простой электронной подписью	
Информация о владельце:	
ΦИΟ: Ястребов Олег Алектанирови State Autonomous Educational In	stitution of Higher Education
Должность: Ректор	DEITY OF DUCCIA
Должность: Ректор Дата подписания: 04.10.2024 14:01:30 <b>FRIENDSHIP UNIVE</b>	LKSII I OF KUSSIA
Уникальный программный ключ: NAMIED AFTER PATRIC	E LUMUMBA
ca953a0120d891083f939673078ef1a989dae18a RUDN Universit	ity

#### **Institute of Medicine**

educational division (faculty/institute/academy) as higher education programme developer

## **COURSE SYLLABUS**

Pharmacology

course title

#### **Recommended by the Didactic Council for the Education Field of:**

# 31.05.03 Dentistry

field of studies / specialty code and title

# The course instruction is implemented within the professional education programme of higher education:

#### Dentistry

higher education programme profile/specialization title

# 1. COURSE GOAL(s)

The goal of the course **"Pharmacology"** is to equip students with the system of knowledge about the principles of drugs classification, their mechanisms of action, pharmacological effects, indications and contraindications for use; the principles of combining drugs, the risk of adverse side effects and their prevention, rules of drugs prescription and drug rational administration.

# 2. REQUIREMENTS FOR LEARNING OUTCOMES

Mastering the course (module) "Pharmacology" is aimed at the development of the following competences /competences in part: UC-3, GPC-5, GPC-13, PC-6.

Competence	Competence descriptor	Competence formation indicators
code		(within this course)
UC-3	UC-3. Being able to organize and supervise teamwork developing a team strategy at the same time to achieve the set goal.	UC-3.3. Solving conflicts and contradictions that may arise in the course of business communication taking into account the interests of all the parties involved.
	CPC 6 Daing able to pressribe	GPC-6.3. Assessing the possible side effects of taking medicinal drugs.
GPC-6	GPC-6. Being able to prescribe non-drug and drug treatment,	GPC-6.4. Providing medical care to a dental patient in emergency or urgent forms.
	monitor its efficacy and safety when solving professional tasks	GPC-6.9. Evaluating the efficacy and safety of using medicinal drugs, medical devices and other methods of treatment at a dental appointment.
GPC-13	GPC-13. Being able to understand the operation principles of modern IT and use them to solve the professional	GPC-13.1. Using information technology in professional activity and observing the information security rules. Information and communication media and technology in professional activity.
	tasks	GPC-13.2. Observing the information security rules in professional activity.
	PC-6. Being able to analyze and present in public medical	PC-6.1. Searching for medical information based on evidence-based medicine, interpreting data from scientific publications and/or preparing a presentation to make medical information, the results of scientific research public.
PC-6	information based on evidence- based medicine, participate in scientific research, introduce new methods and techniques aimed at protecting public health	PC-6.2. Developing algorithms for the examination and treatment of adults and children with dental diseases in accordance with the principles of evidence-based medicine, as well as searching and interpreting medical information based on evidence-based medicine.
		PC-6.3. Conducting public presentation of

Table 2.1. List of competences that students acquire through the course study

	medical information based on evidence-based medicine/ partial participation in scientific research.
--	---

# **3.COURSE IN HIGHER EDUCATION PROGRAMME STRUCTURE**

The course refers to the core/variable/elective\* component of (B1) block of the higher educational programme curriculum. \* - Underline whatever applicable.

Within the higher education programme students also master other (modules) and / or internships that contribute to the achievement of the expected learning outcomes as results of the course study.

Compete Compating descriptor Previous	Subsequent equipos/modules*
contribute to the achievement of the expected learning outc	omes as the course study results
Table 3.1. The list of the higher education program	ne components/disciplines that

Compete nce code	Competence descriptor	Previous courses/modules*	Subsequent courses/modules*
UC – 3	Being able to organize and supervise teamwork developing a team strategy at the same time to achieve the set goal.	-	Observing and Assisting a Dentist (General Dentistry), Including Research Practice Preparation for and Passing the State Exam State Exam (Computer Testing) State Exam (Interdisciplinary Interview)
GPC-6	Being able to prescribe non-drug and drug treatment, monitor its efficacy and safety when solving professional tasks	General Surgery Immunology, Clinical Immunology	Internal illnesses Clinical pharmacology Surgical diseases Health and Safety Neurology Psychiatry and Narcology Pediatrics Operative Dentistry: Cariology and Hard Tissues Diseases Endodontics Gerodontics and Oral Mucosa Diseases Periodontology Oral Surgery Gnathology and Temporo- Mandibular Joint's Functional Diagnostics Prosthodontics (Simple Prosthedics) Prosthodontics of Edentulous Patient Prosthodontics (Complex Prosthetics) Maxillofacial and Orthognathic Surgery Head and Neck Diseases

Compete	Competence descriptor	Previous	Subsequent courses/modules*	
nce code	Competence descriptor	courses/modules*	Subsequent courses/modules	
			Pediatric Maxillofacial	
			Dentistry	
			Maxillofacial Prosthodontics	
			Pediatric Dentistry	
			Orthodontics and Pediatric	
			Prosthodontics	
			Medical Genetics in Dentistry	
			Medical Rehabilitation	
			Clinical Dentistry	
			Implantology and	
			Reconstructive Surgery	
			Modern Endodontics	
			Observing and Assisting a	
			Dentist (Pediatric)	
			Observing and Assisting a	
			Dentist (General Dentistry),	
			Including Research Practice	
			Preparation for and Passing	
			the State Exam	
			State Exam (Computer	
			Testing)	
			State Exam (Interdisciplinary	
			Interview)	
		Latin language	Obstetrics	
		Medical informatics	Medical Rehabilitation	
	Being able to understand		Telemedicine	
	the operation principles		Preparation for and Passing	
GPC-13	of modern IT and use		the State Exam	
	them to solve the		State Exam (Computer	
	professional tasks		Testing)	
			State Exam (Interdisciplinary	
			Interview)	
	Being able to analyze	Physics	Preparation for and Passing	
	and present in public	Medical Informatics	the State Exam	
PC-6	medical information	Human Anatomy -	State Exam (Computer	
	based on evidence-based	Anatomy of Head and	Testing)	
	medicine, participate in scientific research,	Neck	State Exam (Interdisciplinary	
	introduce new methods	Chemistry of Biogenic	Interview)	
	and techniques aimed at	Elements		
	protecting public health			
		e competence matrix of the highe	L	

\* To be filled in according to the competence matrix of the higher education programme.

# 4. COURSE WORKLOAD AND ACADEMIC ACTIVITIES

The total workload of the course "Pharmacology" is to 5 credits (180 academic hours).

*Table 4.1. Types of academic activities during the periods of higher education programme mastering (full-time training)*\*

Type of academic activities		Total	Semesters/training modules			lules
		academic hours	5	6		
Contact academic hours		123	51	72		
including:						
Lectures (LC)		18	0	18		
Lab work (LW)		105	51	54		
Seminars (workshops/tutorials) (S)						
Self-studies		21	18	18		
Evaluation and assessment (exam/passing/failing grade)		18	3	18		
Course workload	academic hours_	180	72	108		
	credits	5	2	3		

\* To be filled in regarding the higher education programme correspondence training mode.

# **5. COURSE CONTENTS**

Course module title	Course module contents (topics)	Academic activities types
Module 1.	1. Recipe. Introduction to Pharmacology.	Lw
General	Types of prescriptions. Formulation rules in the Russian	
Pharmacolo	Federation. Types of dosage forms. ATC classification.	
gy	<b>2. Basic principles of pharmacodynamics</b> Mechanisms of drug action. Antagonists, agonists, partial agonists. Target molecules of drugs (receptors, enzymes, ion channels). Types of pharmacological response: expected pharmacological response, hyperreactivity, tachyphylaxis, idiosyncrasy. The relationship between pharmacokinetics and pharmacodynamics. The concept of a therapeutic index, a therapeutic range. Therapeutic drug monitoring (indications, significance, interpretation of results). Pharmacodynamic interaction of drugs.	Lw
	<b>3. Basic principles of pharmacokinetics.</b> Basic pharmacokinetic parameters and their significance. Drug bioavailability, drug absorption pathways, drug distribution volume, degree of binding to blood plasma proteins, drug metabolism, drug elimination, half-life, drug excretion routes, clearance. Factors affecting the value of pharmacokinetic parameters. Pharmacokinetic curve. Pharmacokinetic interaction of drugs.	Lw

#### Table 5.1. Course contents and academic activities types

Module 2.	1.1. Drugs affecting afferent innervation. Local	Lw
Drugs	anesthetics.	LW
affecting	Classification. Pharmacodynamics of the drug group,	
afferent and	mechanism of action. Pharmacokinetic parameters of the drug	
efferent	group. Indications. Contraindications Adverse reactions. Drug	
innervation	interaction. Application in special categories of patients.	
inner vation	2.2. Cholinergic agents.	Lw
	Anticholinergics. Cholinomimetics.	Lw
	Classification. Pharmacodynamics of groups of drugs, mechanism of action. Pharmacokinetic parameters of drug	
	· · ·	
	groups. Indications. Contraindications Adverse reactions. Drug	
	interaction. Use in special categories of patients.	T
	2.3. Adrenomimetics and sympathomimetics	Lw
	Classification. Pharmacodynamics of groups of drugs,	
	mechanism of action. Pharmacokinetic parameters of drug	
	groups. Indications. Contraindications Adverse reactions. Drug	
	interaction. Use in special categories of patients.	<b>.</b>
	2.4.Adrenolythics and sympatholytics.	Lw
	Classification. Pharmacodynamics of groups of drugs,	
	mechanism of action. Pharmacokinetic parameters of drug	
	groups. Indications. Contraindications Adverse reactions. Drug	
	interaction. Use in special categories of patients.	-
Module 3.	3.1. Diuretics.	Lw
Pharmacolo	Carbonic anhydrase inhibitors (acetazolamide). Osmodiuretics	
gy of drugs	(mannitol). Loop diuretics (bumetamide, furosemide, ethacrynic	
groups.	acid, torasemide). Diuretics acting on the cortical segment of	
Drugs	Henle's loop (hydrochlorothiazide, clopamide, chlorthalidone,	
affecting the	metolazone, indapamide). Potassium-sparing diuretics	
cardiovascul	(spironolactone, eplerenone, amiloride, triamterene).	
ar system	Classification. Pharmacodynamics of the drug group,	
	mechanism of action. Pharmacokinetic parameters of the drug	
	group. Indications. Contraindications Adverse reactions. Drug	
	interaction. Use in special categories of patients.	-
	3.2. Lipid-lowering agents	Lw
	Statins (fluvastatin, simvastatin, pravastatin, atorvastatin,	
	rosuvastatin); fibrates (clofibrate, bezafibrate, gemfibrozil);	
	derivatives of nicotinic acid (niacin, enduracin); bile acid	
	sequestrants (cholestyramine, colestipol, colesevelam); an	
	inhibitor of intestinal cholesterol absorption (ezetimibe).	
	Classification. Pharmacodynamics of the drug group,	
	mechanism of action. Pharmacokinetic parameters of the drug	
	group. Indications. Contraindications Adverse reactions. Drug	
	interaction. Use in special categories of patients.	

Pathways to affect the renin-angiotensin system (RAS):         pharmacology of ACE inhibitors (captopril, enalapril, perindopril, quinapril, moexipril, ramipril, fosinopril, trandolapril, spirapril, lisinopril) and angiotensin receptor blockers (valsartan, candesartan, losartan). Tactics of prescribing ACE inhibitors and angiotensin receptor blockers in hypertension and CHF. Dihydropyridine calcium antagonists: nifedipine, nimodipine, felodipine, amlodipine: pharmacology and place in the treatment of angina pectoris and hypertension. Centrally acting drugs: alpha2-adrenergic agonists (methyldopa, guanfacine, clonidine) and agonists of I1 - imidazoline receptors. Ganglion blockers: azamethonium bromide (penamine), benzohexonium. Features of use in hypertensive crisis. Nitrates (nitroglycerin, isosorbide dinitrate, isosorbide-5-mononitrate, molsidomine): pharmacology, place in the treatment of coronary artery disease. Nitrate tolerance and ways to overcome it.       Lw         3.4. Antianginal drugs       Lw         1) reducing myocardial oxygen demand (b-blockers);       Lw         2) increasing the delivery of oxygen to the heart (coronary dilators of the myotropic antispasmodic and adenosine type of action);       Lw         3) reducing myocardial oxygen demand and increasing oxygen delivery to the heart (nitrates, calcium antagonists).       Lw         Classification. Pharmacokinetic parameters of the drug group, mechanism of action. Pharmacokinetic parameters of the drug group, indications. Contraindications Adverse reactions. Drug interaction. Use in special categories of patients.       Lw         Class I antiarrhythmic drugs (sodium channel blockers). Subclasses Ia (quinidine, novocainamide, disopyramide, aymaline). Ib (lidocaine, mexiletine,	3.3.Antihypertensive drugs	Lw
pharmacology of ACE inhibitors (captopril, enalapril, perindopril, quinapril, moexipril, ramipril, fosinopril, trandolapril, spirapril, lisinopril) and angiotensin receptor blockers (valsartan, candesartan, losartan). Tactics of prescribing ACE inhibitors and angiotensin receptor blockers in hypertension and CHF. Dihydropyridine calcium antagonists: nifedipine, nimodipine, felodipine, amlodipine: pharmacology and place in the treatment of angina pectoris and hypertension. Centrally acting drugs: alpha2-adrenergic agonists (methyldopa, guanfacine, clonidine) and agonists of II - imidazoline receptors. Ganglion blockers: azamethonium bromide (penamine), benzohexonium. Features of use in hypertensive crisis. Nitrates (nitroglycerin, isosorbide dinitrate, isosorbide-5-mononitrate, molsidomine): pharmacology, place in the treatment of coronary artery disease. Nitrate tolerance and ways to overcome it.       Lw         3.4. Antianginal drugs       Lw         1) reducing myocardial oxygen demand (b-blockers);       Lw         3) reducing myocardial oxygen demand and increasing oxygen delivery to the heart (nitrates, calcium antagonists). Classification. Pharmacodynamics of the drug group, mechanism of action. Pharmacodynamics of the drug group, Indications. Contraindications Adverse reactions. Drug interaction. Use in special categories of patients.       Lw         3.5. Antiarrhythmic drugs.       Lw         Class I antiarrhythmic drugs (sodium channel blockers). Subclasses Ia (quinidine, novocainamide, disopyramide, aymaline), Ib (lidocaine, mexiletine, trimecaine, diphenin), Ic (etmozine, etacizin, propafenone, flecainide) - clinical pharmacology, indications for prescription, changes in ECG during treatment.         Class I antiarrhythmic drugs: Beta-blockers: nonselective (propranolol,		
perindopril,       quinapril,       moexipril,       ramipril,       fosinopril,         trandolapril,       spirapril,       lisinopril)       and angiotensin receptor         blockers       (valsartan,       candesartan,       losartan).       Tactics       of         prescribing ACE       inhibitors and angiotensin receptor       blockers:       inperceptor       blockers:       inperceptor         ifedipine,       nimodipine,       felodipine,       anlodipine:       pharmacology         and place in the treatment of angina pectoris and hypertension.       Centrally acting drugs:       alpha2-adrenergic agonists (methyldopa,         guanfacine,       clonidine) and agonists of II - imidazoline receptors.       Ganglion       blockers:       azamethonium       brombide       brombide-5-         monitrate,       molsidomine):       pharmacology,       place in       the       treatment of coronary artery disease. Nitrate tolerance and ways       to       overcome it.         3.4.       Antianginal drugs       l       Lw       l       l       lw         1) reducing myocardial oxygen demand and increasing oxygen       delivery to the heart (nitrates, calcium antagonists).       Law         1) reducing myocardial oxygen demand and increasing oxygen       delivery to the heart (nitrates, calcium antagonists).       Law <td></td> <td></td>		
trandolapril, spirapril, lisinopril) and angiotensin receptor blockers (valsartan, candesartan, losartan). Tactics of prescribing ACE inhibitors and angiotensin receptor blockers in hypertension and CHF. Dihydropyridine calcium antagonists: nifedipine, nimodipine, felodipine, amlodipine: pharmacology and place in the treatment of angina pectoris and hypertension. Centrally acting drugs: alpha2-adrenergic agonists (methyldopa, guanfacine, clonidine) and agonists of II - imidazoline receptors. Ganglion blockers: azamethonium bromide (penamine), benzohexonium. Features of use in hypertensive crisis. Nitrates (nitroglycerin, isosorbide dinitrate, isosorbide-5- mononitrate, molsidomine): pharmacology, place in the treatment of coronary artery disease. Nitrate tolerance and ways to overcome it.Lw <b>3.4. Antianginal drugs</b> 1) reducing myocardial oxygen demand (b-blockers); 2) increasing the delivery of oxygen to the heart (coronary dilators of the myotropic antispasmodic and adenosine type of action); 3) reducing myocardial oxygen demand and increasing oxygen delivery to the heart (nitrates, calcium antagonists). Classification. Pharmacodynamics of the drug group, mechanism of action. Pharmacokinetic parameters of the drug group. Indications. Contraindications Adverse reactions. Drug interaction. Use in special categories of patients.Lw <b>3.5. Antiarrhythmic drugs</b> (Elass I antiarrhythmic drugs (sodium channel blockers). Subclasses la (quinidine, novocainamide, disopyramide, aymaline), lb (idocaine, mexiletine, trimecaine, diphenin), Ic (etmozine, etacizin, propafenone, flecanide) - clinical pharmacology, indications for prescription, changes in ECG during treatment. Class II antiarrhythmic drugs: Beta-blockers: nonselective (propranolol, madolol, sotalol), selective (oxprenolol, metoprolol, atenolol, betaxolol, bisoprolol, neb		
blockers (valsartan, candesartan, losartan). Tactics of prescribing ACE inhibitors and angiotensin receptor blockers in hypertension and CHF. Dihydropyridine calcium antagonists: nifedipine, nimodipine, felodipine, amlodipine: pharmacology and place in the treatment of angina pectoris and hypertension. Centrally acting drugs: alpha2-adrenergic agonists (methyldopa, guanfacine, clonidine) and agonists of II - imidazoline receptors. Ganglion blockers: azamethonium bromide (penamine), benzohexonium. Features of use in hypertensive crisis. Nitrates (nitroglycerin, isosorbide dinitrate, isosorbide-5- mononitrate, molsidomine): pharmacology, place in the treatment of coronary artery disease. Nitrate tolerance and ways to overcome it. <b>3.4. Antianginal drugs</b> 1) reducing myocardial oxygen demand (b-blockers); 2) increasing the delivery of oxygen to the heart (coronary dilators of the myotropic antispasmodic and adenosine type of action); 3) reducing myocardial oxygen demand and increasing oxygen delivery to the heart (nitrates, calcium antagonists). Classification. Pharmacodynamics of the drug group, mechanism of action. Pharmacokinetic parameters of the drug group. Indications. Contraindications Adverse reactions. Drug interaction. Use in special categories of patients. <b>3.5. Antiarrhythmic drugs</b> . Class I antiarrhythmic drugs (sodium channel blockers). Subclasses Ia (quinidine, novocainamide, disopyramide, aymaline), Ib (lidocaine, mexiletine, trimecaine, diphenin), Ic (etmozine, etacizin, propafenone, flecainide) - clinical pharmacology, indications for prescription, changes in ECG during treatment. Class II antiarrhythmic drugs: Beta-blockers: nonselective (propranolol, aetolol, sotalol), selective (oxprenolol, metoprolol, atenolol, betaxolol, bisoprolol, nebivolol), drugs		
prescribing ACE inhibitors and angiotensin receptor blockers in         hypertension and CHF. Dihydropyridine calcium antagonists:         nifedipine, nimodipine, felodipine, amlodipine: pharmacology         and place in the treatment of angina pectoris and hypertension.         Centrally acting drugs: alpha2-adrenergic agonists (methyldopa,         guanfacine, clonidine) and agonists of I1 - imidazoline receptors.         Ganglion blockers: azamethonium bromide (penamine),         benzohexonium. Features of use in hypertensive crisis.         Nitrates (nitroglycerin, isosorbide dinitrate, isosorbide-5-         mononitrate, molsidomine): pharmacology, place in the         treatment of coronary artery disease. Nitrate tolerance and ways         to overcome it. <b>3.4. Antianginal drugs</b> 1) reducing myocardial oxygen demand (b-blockers);         2) increasing the delivery of oxygen to the heart (coronary         dilators of the myotropic antispasmodic and adenosine type of         action);         3) reducing myocardial oxygen demand and increasing oxygen         delivery to the heart (nitrates, calcium antagonists).         Classification. Pharmacodynamics of the drug group,         mechanism of action. Pharmacokinetic parameters of the drug         group. Indications. Contraindications Adverse reactions. Drug         interaction. Use in special categories of patients. <b>3.5</b>		
hypertension and CHF. Dihydropyridine calcium antagonists: nifedipine, nimodipine, felodipine, amlodipine: pharmacology and place in the treatment of angina pectoris and hypertension. Centrally acting drugs: alpha2-adrenergic agonists (methyldopa, guanfacine, clonidine) and agonists of 11 - imidazoline receptors. Ganglion blockers: azamethonium bromide (penamine), benzohexonium. Features of use in hypertensive crisis. Nitrates (nitroglycerin, isosorbide dinitrate, isosorbide-5- mononitrate, molsidomine): pharmacology, place in the treatment of coronary artery disease. Nitrate tolerance and ways to overcome it.Lw3.4. Antianginal drugs 1) reducing myocardial oxygen demand (b-blockers); 2) increasing the delivery of oxygen to the heart (coronary dilators of the myotropic antispasmodic and adenosine type of action); 3) reducing myocardial oxygen demand and increasing oxygen delivery to the heart (nitrates, calcium antagonists). Classification. Pharmacodynamics of the drug group, mechanism of action. Pharmacokinetic parameters of the drug group. Indications. Contraindications Adverse reactions. Drug interaction. Use in special categories of patients.Lw3.5. Antiarrhythmic drugs aymaline), lb (lidocaine, mexiletine, trimecaine, diphenin), lc (etmozine, etacizin, propafenone, flecainide) - clinical pharmacology, indications for prescription, changes in ECG during treatment. Class II antiarrhythmic drugs: Beta-blockers: nonselective (propranolol, nadolol, sotalol), selective (oxprenolol, metoprolol, atenolol, betaxolol, bisoprolol, nebivolol), drugs		
<ul> <li>nifedipine, nimodipine, felodipine, amlodipine: pharmacology and place in the treatment of angina pectoris and hypertension. Centrally acting drugs: alpha2-adrenergic agonists (methyldopa, guanfacine, clonidine) and agonists of II - imidazoline receptors. Ganglion blockers: azamethonium bromide (penamine), benzohexonium. Features of use in hypertensive crisis. Nitrates (nitroglycerin, isosorbide dinitrate, isosorbide-5- mononitrate, molsidomine): pharmacology, place in the treatment of coronary artery disease. Nitrate tolerance and ways to overcome it.</li> <li>3.4. Antianginal drugs         <ol> <li>reducing myocardial oxygen demand (b-blockers);</li> <li>increasing the delivery of oxygen to the heart (coronary dilators of the myotropic antispasmodic and adenosine type of action);</li> <li>reducing myocardial oxygen demand and increasing oxygen delivery to the heart (nitrates, calcium antagonists).</li> <li>Classification. Pharmacodynamics of the drug group, mechanism of action. Pharmacokinetic parameters of the drug group. Indications. Contraindications Adverse reactions. Drug interaction. Use in special categories of patients.</li> </ol> </li> <li>Subclasses Ia (quinidine, novocainamide, disopyramide, aymaline), Ib (lidocaine, mexiletine, trimecaine, diphenin), Ic (etmozine, etacizin, propafenone, flecainide) - clinical pharmacology, indications for prescription, changes in ECG during treatment.</li> <li>Class II antiarrhythmic drugs: Beta-blockers: nonselective (propranolol, nadolol, sotalol), selective (oxprenolol, metoprolol, atenolol, betaxolol, bisoprolol, nebivolol), drugs</li> </ul>		
and place in the treatment of angina pectoris and hypertension. Centrally acting drugs: alpha2-adrenergic agonists (methyldopa, guanfacine, clonidine) and agonists of II - imidazoline receptors. Ganglion blockers: azamethonium bromide (penamine), benzohexonium. Features of use in hypertensive crisis. Nitrates (nitroglycerin, isosorbide dinitrate, isosorbide-5- mononitrate, molsidomine): pharmacology, place in the treatment of coronary artery disease. Nitrate tolerance and ways to overcome it. <b>3.4. Antianginal drugs</b> 1) reducing myocardial oxygen demand (b-blockers); 2) increasing the delivery of oxygen to the heart (coronary dilators of the myotropic antispasmodic and adenosine type of action); 3) reducing myocardial oxygen demand and increasing oxygen delivery to the heart (nitrates, calcium antagonists). Classification. Pharmacodynamics of the drug group, mechanism of action. Pharmacokinetic parameters of the drug group. Indications. Contraindications Adverse reactions. Drug interaction. Use in special categories of patients. <b>3.5. Antiarrhythmic drugs</b> Subclasses Ia (quinidine, novocainamide, disopyramide, aymaline), Ib (lidocaine, mexiletine, trimecaine, diphenin), Ic (etmozine, etacizin, propafenone, flecainide) - clinical pharmacology, indications for prescription, changes in ECG during treatment. Class II antiarrhythmic drugs: Beta-blockers: nonselective (propranolol, nadolol, sotalol), selective (oxprenolol, metoprolol, atenolol, betaxolol, bisoprolol, nebivolol), drugs		
Centrally acting drugs: alpha2-adrenergic agonists (methyldopa, guanfacine, clonidine) and agonists of II - imidazoline receptors. Ganglion blockers: azamethonium bromide (penamine), benzohexonium. Features of use in hypertensive crisis. Nitrates (nitroglycerin, isosorbide dinitrate, isosorbide-5- mononitrate, molsidomine): pharmacology, place in the treatment of coronary artery disease. Nitrate tolerance and ways to overcome it.Lw3.4. Antianginal drugs 1) reducing myocardial oxygen demand (b-blockers); 2) increasing the delivery of oxygen to the heart (coronary dilators of the myotropic antispasmodic and adenosine type of action); 3) reducing myocardial oxygen demand and increasing oxygen delivery to the heart (nitrates, calcium antagonists). Classification. Pharmacodynamics of the drug group, mechanism of action. Pharmacokinetic parameters of the drug group. Indications. Contraindications Adverse reactions. Drug interaction. Use in special categories of patients.Lw3.5. Antiarrhythmic drugs. Class I antiarrhythmic drugs (sodium channel blockers). Subclasses Ia (quinidine, novocainamide, disopyramide, aymaline), Ib (lidocaine, mexiletine, trimecaine, diphenin), Ic (etmozine, etacizin, propafenone, flecainide) - clinical pharmacology, indications for prescription, changes in ECG during treatment. Class II antiarrhythmic drugs: Beta-blockers: nonselective (propranolol, nadolol, sotalol), selective (oxprenolol, metoprolol, atenolol, betaxolol, bisoprolol, nebivolol), drugs		
guanfacine, clonidine) and agonists of II - imidazoline receptors. Ganglion blockers: azamethonium bromide (penamine), benzohexonium. Features of use in hypertensive crisis. Nitrates (nitroglycerin, isosorbide dinitrate, isosorbide-5- mononitrate, molsidomine): pharmacology, place in the treatment of coronary artery disease. Nitrate tolerance and ways to overcome it.Lw <b>3.4. Antianginal drugs</b> 1) reducing myocardial oxygen demand (b-blockers); 2) increasing the delivery of oxygen to the heart (coronary dilators of the myotropic antispasmodic and adenosine type of action); 3) reducing myocardial oxygen demand and increasing oxygen delivery to the heart (nitrates, calcium antagonists). Classification. Pharmacodynamics of the drug group, mechanism of action. Pharmacokinetic parameters of the drug group. Indications. Contraindications Adverse reactions. Drug interaction. Use in special categories of patients.Lw <b>3.5. Antiarrhythmic drugs.</b> Class I antiarrhythmic drugs (sodium channel blockers). Subclasses Ia (quinidine, novocainamide, disopyramide, aymaline), Ib (lidocaine, mexiletine, trimecaine, diphenin), Ic (etmozine, etacizin, propafenone, flecainide) - clinical pharmacology, indications for prescription, changes in ECG during treatment. Class II antiarrhythmic drugs: Beta-blockers: nonselective (propranolol, nadolol, sotalol), selective (oxprenolol, metoprolol, atenolol, betaxolol, bisoprolol, nebivolol), drugs		
Ganglion blockers: azamethonium bromide (penamine), benzohexonium. Features of use in hypertensive crisis. Nitrates (nitroglycerin, isosorbide dinitrate, isosorbide-5- mononitrate, molsidomine): pharmacology, place in the treatment of coronary artery disease. Nitrate tolerance and ways to overcome it.Lw3.4. Antianginal drugs 1) reducing myocardial oxygen demand (b-blockers); 2) increasing the delivery of oxygen to the heart (coronary dilators of the myotropic antispasmodic and adenosine type of action); 3) reducing myocardial oxygen demand and increasing oxygen delivery to the heart (nitrates, calcium antagonists). Classification. Pharmacodynamics of the drug group, 	Centrally acting drugs: alpha2-adrenergic agonists (methyldopa,	
benzohexonium. Features of use in hypertensive crisis. Nitrates (nitroglycerin, isosorbide dinitrate, isosorbide-5- mononitrate, molsidomine): pharmacology, place in the treatment of coronary artery disease. Nitrate tolerance and ways to overcome it.Lw <b>3.4. Antianginal drugs</b> 1) reducing myocardial oxygen demand (b-blockers); 2) increasing the delivery of oxygen to the heart (coronary dilators of the myotropic antispasmodic and adenosine type of action); 3) reducing myocardial oxygen demand and increasing oxygen delivery to the heart (nitrates, calcium antagonists). Classification. Pharmacodynamics of the drug group, mechanism of action. Pharmacokinetic parameters of the drug group. Indications. Contraindications Adverse reactions. Drug interaction. Use in special categories of patients.Lw <b>3.5. Antiarrhythmic drugs.</b> Class I antiarrhythmic drugs (sodium channel blockers). Subclasses Ia (quinidine, novocainamide, disopyramide, aymaline), Ib (lidocaine, mexiletine, trimecaine, diphenin), Ic (etmozine, etacizin, propafenone, flecainide) - clinical pharmacology, indications for prescription, changes in ECG during treatment. Class II antiarrhythmic drugs: Beta-blockers: nonselective (propranolol, nadolol, sotalol), selective (oxprenolol, metoprolol, atenolol, betaxolol, bisoprolol, nebivolol), drugs	guanfacine, clonidine) and agonists of I1 - imidazoline receptors.	
Nitrates(nitroglycerin, isosorbide dinitrate, isosorbide-5- mononitrate, molsidomine): pharmacology, place in the treatment of coronary artery disease. Nitrate tolerance and ways to overcome it.Lw <b>3.4. Antianginal drugs</b> 1) reducing myocardial oxygen demand (b-blockers); 2) increasing the delivery of oxygen to the heart (coronary dilators of the myotropic antispasmodic and adenosine type of action); 3) reducing myocardial oxygen demand and increasing oxygen delivery to the heart (nitrates, calcium antagonists). Classification. Pharmacodynamics of the drug group, mechanism of action. Pharmacokinetic parameters of the drug group. Indications. Contraindications Adverse reactions. Drug interaction. Use in special categories of patients.Lw <b>3.5. Antiarrhythmic drugs.</b> Class I antiarrhythmic drugs (sodium channel blockers). Subclasses Ia (quinidine, novocainamide, disopyramide, aymaline), Ib (lidocaine, mexiletine, trimecaine, diphenin), Ic (etmozine, etacizin, propafenone, flecainide) - clinical pharmacology, indications for prescription, changes in ECG during treatment. Class II antiarrhythmic drugs: Beta-blockers: nonselective (propranolol, nadolol, sotalol), selective (oxprenolol, metoprolol, atenolol, betaxolol, bisoprolol, nebivolol), drugs	Ganglion blockers: azamethonium bromide (penamine),	
mononitrate, molsidomine): pharmacology, place in the treatment of coronary artery disease. Nitrate tolerance and ways to overcome it. <b>3.4. Antianginal drugs</b> 1) reducing myocardial oxygen demand (b-blockers); 2) increasing the delivery of oxygen to the heart (coronary dilators of the myotropic antispasmodic and adenosine type of action); 3) reducing myocardial oxygen demand and increasing oxygen delivery to the heart (nitrates, calcium antagonists). Classification. Pharmacodynamics of the drug group, mechanism of action. Pharmacokinetic parameters of the drug group. Indications. Contraindications Adverse reactions. Drug interaction. Use in special categories of patients.Lw <b>3.5. Antiarrhythmic drugs</b> (class I antiarrhythmic drugs (sodium channel blockers). Subclasses Ia (quinidine, novocainamide, disopyramide, aymaline), Ib (lidocaine, mexiletine, trimecaine, diphenin), Ic (etmozine, etacizin, propafenone, flecainide) - clinical pharmacology, indications for prescription, changes in ECG during treatment.Lw	benzohexonium. Features of use in hypertensive crisis.	
mononitrate, molsidomine): pharmacology, place in the treatment of coronary artery disease. Nitrate tolerance and ways to overcome it. <b>3.4. Antianginal drugs</b> 1) reducing myocardial oxygen demand (b-blockers); 2) increasing the delivery of oxygen to the heart (coronary dilators of the myotropic antispasmodic and adenosine type of action); 3) reducing myocardial oxygen demand and increasing oxygen delivery to the heart (nitrates, calcium antagonists). Classification. Pharmacodynamics of the drug group, mechanism of action. Pharmacokinetic parameters of the drug group. Indications. Contraindications Adverse reactions. Drug interaction. Use in special categories of patients.Lw <b>3.5. Antiarrhythmic drugs</b> (class I antiarrhythmic drugs (sodium channel blockers). Subclasses Ia (quinidine, novocainamide, disopyramide, aymaline), Ib (lidocaine, mexiletine, trimecaine, diphenin), Ic (etmozine, etacizin, propafenone, flecainide) - clinical pharmacology, indications for prescription, changes in ECG during treatment.Lw		
treatment of coronary artery disease. Nitrate tolerance and ways to overcome it. <b>3.4. Antianginal drugs</b> 1) reducing myocardial oxygen demand (b-blockers); 2) increasing the delivery of oxygen to the heart (coronary dilators of the myotropic antispasmodic and adenosine type of action); 3) reducing myocardial oxygen demand and increasing oxygen delivery to the heart (nitrates, calcium antagonists). Classification. Pharmacodynamics of the drug group, mechanism of action. Pharmacokinetic parameters of the drug group. Indications. Contraindications Adverse reactions. Drug interaction. Use in special categories of patients. <b>3.5. Antiarrhythmic drugs</b> Class I antiarrhythmic drugs (sodium channel blockers). Subclasses Ia (quinidine, novocainamide, disopyramide, aymaline), Ib (lidocaine, mexiletine, trimecaine, diphenin), Ic (etmozine, etacizin, propafenone, flecainide) - clinical pharmacology, indications for prescription, changes in ECG during treatment. Class II antiarrhythmic drugs: Beta-blockers: nonselective (propranolol, nadolol, sotalol), selective (oxprenolol, metoprolol, atenolol, betaxolol, bisoprolol, nebivolol), drugs		
to overcome it.3.4. Antianginal drugs1) reducing myocardial oxygen demand (b-blockers);2) increasing the delivery of oxygen to the heart (coronary dilators of the myotropic antispasmodic and adenosine type of action);3) reducing myocardial oxygen demand and increasing oxygen delivery to the heart (nitrates, calcium antagonists). Classification. Pharmacodynamics of the drug group, mechanism of action. Pharmacokinetic parameters of the drug group. Indications. Contraindications Adverse reactions. Drug interaction. Use in special categories of patients.3.5. Antiarrhythmic drugs. Class I antiarrhythmic drugs (sodium channel blockers). Subclasses Ia (quinidine, novocainamide, disopyramide, aymaline), Ib (lidocaine, mexiletine, trimecaine, diphenin), Ic (etmozine, etacizin, propafenone, flecainide) - clinical pharmacology, indications for prescription, changes in ECG during treatment. Class II antiarrhythmic drugs: Beta-blockers: nonselective (propranolol, nadolol, sotalol), selective (oxprenolol, metoprolol, atenolol, betaxolol, bisoprolol, nebivolol), drugs		
<b>3.4. Antianginal drugs</b> 1) reducing myocardial oxygen demand (b-blockers); 2) increasing the delivery of oxygen to the heart (coronary dilators of the myotropic antispasmodic and adenosine type of action); 3) reducing myocardial oxygen demand and increasing oxygen delivery to the heart (nitrates, calcium antagonists). Classification. Pharmacodynamics of the drug group, mechanism of action. Pharmacokinetic parameters of the drug group. Indications. Contraindications Adverse reactions. Drug interaction. Use in special categories of patients.Lw <b>3.5. Antiarrhythmic drugs.</b> Class I antiarrhythmic drugs (sodium channel blockers). Subclasses Ia (quinidine, novocainamide, disopyramide, aymaline), Ib (lidocaine, mexiletine, trimecaine, diphenin), Ic (etmozine, etacizin, propafenone, flecainide) - clinical pharmacology, indications for prescription, changes in ECG during treatment. Class II antiarrhythmic drugs: Beta-blockers: nonselective (propranolol, nadolol, sotalol), selective (oxprenolol, 		
<ul> <li>1) reducing myocardial oxygen demand (b-blockers);</li> <li>2) increasing the delivery of oxygen to the heart (coronary dilators of the myotropic antispasmodic and adenosine type of action);</li> <li>3) reducing myocardial oxygen demand and increasing oxygen delivery to the heart (nitrates, calcium antagonists).</li> <li>Classification. Pharmacodynamics of the drug group, mechanism of action. Pharmacokinetic parameters of the drug group. Indications. Contraindications Adverse reactions. Drug interaction. Use in special categories of patients.</li> <li><b>3.5. Antiarrhythmic drugs.</b></li> <li>Class I antiarrhythmic drugs (sodium channel blockers). Subclasses Ia (quinidine, novocainamide, disopyramide, aymaline), Ib (lidocaine, mexiletine, trimecaine, diphenin), Ic (etmozine, etacizin, propafenone, flecainide) - clinical pharmacology, indications for prescription, changes in ECG during treatment.</li> <li>Class II antiarrhythmic drugs: Beta-blockers: nonselective (propranolol, nadolol, sotalol), selective (oxprenolol, metoprolol, atenolol, betaxolol, bisoprolol, nebivolol), drugs</li> </ul>		Lw
<ul> <li>2) increasing the delivery of oxygen to the heart (coronary dilators of the myotropic antispasmodic and adenosine type of action);</li> <li>3) reducing myocardial oxygen demand and increasing oxygen delivery to the heart (nitrates, calcium antagonists).</li> <li>Classification. Pharmacodynamics of the drug group, mechanism of action. Pharmacokinetic parameters of the drug group. Indications. Contraindications Adverse reactions. Drug interaction. Use in special categories of patients.</li> <li><b>3.5. Antiarrhythmic drugs.</b></li> <li>Class I antiarrhythmic drugs (sodium channel blockers). Subclasses Ia (quinidine, novocainamide, disopyramide, aymaline), Ib (lidocaine, mexiletine, trimecaine, diphenin), Ic (etmozine, etacizin, propafenone, flecainide) - clinical pharmacology, indications for prescription, changes in ECG during treatment.</li> <li>Class II antiarrhythmic drugs: Beta-blockers: nonselective (propranolol, nadolol, sotalol), selective (oxprenolol, metoprolol, atenolol, betaxolol, bisoprolol, nebivolol), drugs</li> </ul>		
dilators of the myotropic antispasmodic and adenosine type of action);3) reducing myocardial oxygen demand and increasing oxygen delivery to the heart (nitrates, calcium antagonists).Classification. Pharmacodynamics of the drug group, mechanism of action. Pharmacokinetic parameters of the drug group. Indications. Contraindications Adverse reactions. Drug interaction. Use in special categories of patients. <b>3.5. Antiarrhythmic drugs.</b> Class I antiarrhythmic drugs (sodium channel blockers). Subclasses Ia (quinidine, novocainamide, disopyramide, aymaline), Ib (lidocaine, mexiletine, trimecaine, diphenin), Ic (etmozine, etacizin, propafenone, flecainide) - clinical pharmacology, indications for prescription, changes in ECG during treatment. Class II antiarrhythmic drugs: Beta-blockers: nonselective (propranolol, nadolol, sotalol), selective (oxprenolol, metoprolol, atenolol, betaxolol, bisoprolol, nebivolol), drugs		
action); 3) reducing myocardial oxygen demand and increasing oxygen delivery to the heart (nitrates, calcium antagonists). Classification. Pharmacodynamics of the drug group, mechanism of action. Pharmacokinetic parameters of the drug group. Indications. Contraindications Adverse reactions. Drug interaction. Use in special categories of patients. <b>3.5. Antiarrhythmic drugs.</b> Class I antiarrhythmic drugs (sodium channel blockers). Subclasses Ia (quinidine, novocainamide, disopyramide, aymaline), Ib (lidocaine, mexiletine, trimecaine, diphenin), Ic (etmozine, etacizin, propafenone, flecainide) - clinical pharmacology, indications for prescription, changes in ECG during treatment. Class II antiarrhythmic drugs: Beta-blockers: nonselective (propranolol, nadolol, sotalol), selective (oxprenolol, metoprolol, atenolol, betaxolol, bisoprolol, nebivolol), drugs		
<ul> <li>3) reducing myocardial oxygen demand and increasing oxygen delivery to the heart (nitrates, calcium antagonists). Classification. Pharmacodynamics of the drug group, mechanism of action. Pharmacokinetic parameters of the drug group. Indications. Contraindications Adverse reactions. Drug interaction. Use in special categories of patients.</li> <li><b>3.5. Antiarrhythmic drugs.</b> Class I antiarrhythmic drugs (sodium channel blockers). Subclasses Ia (quinidine, novocainamide, disopyramide, aymaline), Ib (lidocaine, mexiletine, trimecaine, diphenin), Ic (etmozine, etacizin, propafenone, flecainide) - clinical pharmacology, indications for prescription, changes in ECG during treatment. Class II antiarrhythmic drugs: Beta-blockers: nonselective (propranolol, nadolol, sotalol), selective (oxprenolol, metoprolol, atenolol, betaxolol, bisoprolol, nebivolol), drugs</li> </ul>		
delivery to the heart (nitrates, calcium antagonists). Classification. Pharmacodynamics of the drug group, mechanism of action. Pharmacokinetic parameters of the drug group. Indications. Contraindications Adverse reactions. Drug interaction. Use in special categories of patients.Lw <b>3.5. Antiarrhythmic drugs.</b> Class I antiarrhythmic drugs (sodium channel blockers). Subclasses Ia (quinidine, novocainamide, disopyramide, aymaline), Ib (lidocaine, mexiletine, trimecaine, diphenin), Ic (etmozine, etacizin, propafenone, flecainide) - clinical pharmacology, indications for prescription, changes in ECG during treatment. Class II antiarrhythmic drugs: Beta-blockers: nonselective (propranolol, nadolol, sotalol), selective (oxprenolol, metoprolol, atenolol, betaxolol, bisoprolol, nebivolol), drugs		
Classification. Pharmacodynamics of the drug group, mechanism of action. Pharmacokinetic parameters of the drug group. Indications. Contraindications Adverse reactions. Drug interaction. Use in special categories of patients. <b>3.5. Antiarrhythmic drugs.</b> Class I antiarrhythmic drugs (sodium channel blockers). Subclasses Ia (quinidine, novocainamide, disopyramide, aymaline), Ib (lidocaine, mexiletine, trimecaine, diphenin), Ic (etmozine, etacizin, propafenone, flecainide) - clinical pharmacology, indications for prescription, changes in ECG during treatment. Class II antiarrhythmic drugs: Beta-blockers: nonselective (propranolol, nadolol, sotalol), selective (oxprenolol, metoprolol, atenolol, betaxolol, bisoprolol, nebivolol), drugs		
mechanism of action. Pharmacokinetic parameters of the drug group. Indications. Contraindications Adverse reactions. Drug interaction. Use in special categories of patients.Lw <b>3.5. Antiarrhythmic drugs.</b> Class I antiarrhythmic drugs (sodium channel blockers). Subclasses Ia (quinidine, novocainamide, disopyramide, aymaline), Ib (lidocaine, mexiletine, trimecaine, diphenin), Ic (etmozine, etacizin, propafenone, flecainide) - clinical pharmacology, indications for prescription, changes in ECG during treatment. Class II antiarrhythmic drugs: Beta-blockers: nonselective (propranolol, nadolol, sotalol), selective (oxprenolol, metoprolol, atenolol, betaxolol, bisoprolol, nebivolol), drugs		
group. Indications. Contraindications Adverse reactions. Drug interaction. Use in special categories of patients.Drug <b>3.5. Antiarrhythmic drugs.</b> Class I antiarrhythmic drugs (sodium channel blockers). Subclasses Ia (quinidine, novocainamide, disopyramide, aymaline), Ib (lidocaine, mexiletine, trimecaine, diphenin), Ic (etmozine, etacizin, propafenone, flecainide) - clinical pharmacology, indications for prescription, changes in ECG during treatment. Class II antiarrhythmic drugs: Beta-blockers: nonselective (propranolol, nadolol, sotalol), selective (oxprenolol, metoprolol, atenolol, betaxolol, bisoprolol, nebivolol), drugs		
interaction. Use in special categories of patients.Lw <b>3.5. Antiarrhythmic drugs.</b> Class I antiarrhythmic drugs (sodium channel blockers). Subclasses Ia (quinidine, novocainamide, disopyramide, aymaline), Ib (lidocaine, mexiletine, trimecaine, diphenin), Ic (etmozine, etacizin, propafenone, flecainide) - clinical pharmacology, indications for prescription, changes in ECG during treatment. Class II antiarrhythmic drugs: Beta-blockers: nonselective (propranolol, nadolol, sotalol), selective (oxprenolol, metoprolol, atenolol, betaxolol, bisoprolol, nebivolol), drugs	· · · ·	
3.5. Antiarrhythmic drugs. Class I antiarrhythmic drugs (sodium channel blockers). Subclasses Ia (quinidine, novocainamide, disopyramide, aymaline), Ib (lidocaine, mexiletine, trimecaine, diphenin), Ic (etmozine, etacizin, propafenone, flecainide) - clinical pharmacology, indications for prescription, changes in ECG during treatment. Class II antiarrhythmic drugs: Beta-blockers: nonselective (propranolol, nadolol, sotalol), selective (oxprenolol, metoprolol, atenolol, betaxolol, bisoprolol, nebivolol), drugs	•	
Class I antiarrhythmic drugs (sodium channel blockers). Subclasses Ia (quinidine, novocainamide, disopyramide, aymaline), Ib (lidocaine, mexiletine, trimecaine, diphenin), Ic (etmozine, etacizin, propafenone, flecainide) - clinical pharmacology, indications for prescription, changes in ECG during treatment. Class II antiarrhythmic drugs: Beta-blockers: nonselective (propranolol, nadolol, sotalol), selective (oxprenolol, metoprolol, atenolol, betaxolol, bisoprolol, nebivolol), drugs		
Subclasses Ia (quinidine, novocainamide, disopyramide, aymaline), Ib (lidocaine, mexiletine, trimecaine, diphenin), Ic (etmozine, etacizin, propafenone, flecainide) - clinical pharmacology, indications for prescription, changes in ECG during treatment. Class II antiarrhythmic drugs: Beta-blockers: nonselective (propranolol, nadolol, sotalol), selective (oxprenolol, metoprolol, atenolol, betaxolol, bisoprolol, nebivolol), drugs	•	Lw
aymaline), Ib (lidocaine, mexiletine, trimecaine, diphenin), Ic (etmozine, etacizin, propafenone, flecainide) - clinical pharmacology, indications for prescription, changes in ECG during treatment. Class II antiarrhythmic drugs: Beta-blockers: nonselective (propranolol, nadolol, sotalol), selective (oxprenolol, metoprolol, atenolol, betaxolol, bisoprolol, nebivolol), drugs	Class I antiarrhythmic drugs (sodium channel blockers).	
<ul> <li>(etmozine, etacizin, propafenone, flecainide) - clinical pharmacology, indications for prescription, changes in ECG during treatment.</li> <li>Class II antiarrhythmic drugs: Beta-blockers: nonselective (propranolol, nadolol, sotalol), selective (oxprenolol, metoprolol, atenolol, betaxolol, bisoprolol, nebivolol), drugs</li> </ul>	Subclasses Ia (quinidine, novocainamide, disopyramide,	
pharmacology, indications for prescription, changes in ECG during treatment. Class II antiarrhythmic drugs: Beta-blockers: nonselective (propranolol, nadolol, sotalol), selective (oxprenolol, metoprolol, atenolol, betaxolol, bisoprolol, nebivolol), drugs	aymaline), Ib (lidocaine, mexiletine, trimecaine, diphenin), Ic	
during treatment. Class II antiarrhythmic drugs: Beta-blockers: nonselective (propranolol, nadolol, sotalol), selective (oxprenolol, metoprolol, atenolol, betaxolol, bisoprolol, nebivolol), drugs	(etmozine, etacizin, propafenone, flecainide) - clinical	
during treatment. Class II antiarrhythmic drugs: Beta-blockers: nonselective (propranolol, nadolol, sotalol), selective (oxprenolol, metoprolol, atenolol, betaxolol, bisoprolol, nebivolol), drugs	pharmacology, indications for prescription, changes in ECG	
Class II antiarrhythmic drugs: Beta-blockers: nonselective (propranolol, nadolol, sotalol), selective (oxprenolol, metoprolol, atenolol, betaxolol, bisoprolol, nebivolol), drugs		
(propranolol, nadolol, sotalol), selective (oxprenolol, metoprolol, atenolol, betaxolol, bisoprolol, nebivolol), drugs	6	
metoprolol, atenolol, betaxolol, bisoprolol, nebivolol), drugs		
	with their own sympathomimetic activity (oxprenolol,	
pindolokirol-1), drugs with alpha-1-blocking activity (labetalol,		
carvedilol). Beta-blockers in the treatment of CHF.		
,		
Class III antiarrhythmic drugs (potassium channel blockers -		
amiodarone, sotalol, dofetilide, ibutilide): clinical		
pharmacology, indications for prescription, ECG changes while		
prescribing these drugs. Class IV antiarrhythmic drugs (calcium		
antagonists - verapamil, diltiazem): clinical pharmacology,		
indications for prescription, ECG changes while prescribing		
these drugs. Antiarrhythmic drugs: adenosine, potassium salts.	these drugs. Antiarrhythmic drugs: adenosine, potassium salts.	

		<b>T</b>
	<b>3.6. Drugs used in heart failure</b>	Lw
	Drugs with a positive inotropic effect: cardiac glycosides (digoxin), non-glycoside cardiotonics (dopamine, dobutamine,	
	amrinone, milrinone, enoximone, levosimendan). The dosage	
	regimen of cardiac glycosides, depending on the state of the	
	gastrointestinal tract, metabolic and excretion organs in the patient, the number and rhythm of heart contractions, the state of	
	contractility and conductivity of the myocardium, the rate of	
	development of the effect, drug interactions and factors	
	contributing to a change in sensitivity to drugs. Diagnostics,	
	correction and prevention of adverse reactions. Drug	
Module 4.	<ul><li>interactions, adverse drug reactions.</li><li>4.1. Drugs affecting the blood coagulation system.</li></ul>	Lw, Lc
Pharmacolo	Antiplatelet agents: acetylsalicylic acid, clopidogrel, ticlopidine,	Lw, LC
	abciximab, anagrelide, alprostadil, lysine acetylsalicylate. Direct	
gy of drugs		
groups.	anticoagulants: sodium heparin, low molecular weight heparins (sodium enoxaparin, nadroparin, fraxiparin). Indirect	
Drugs		
affecting hemostasis		
and	streptokinase, tissue plasminogen activator (alteplase, prourokinase). Synthetic selective inhibitor of activated factor X	
and hematopoies	(Xa) fondaparinux sodium, rivaroxaban, direct thrombin	
-	-	
is	inhibitor dabigatran. Drugs that increase blood clotting (vitamin	
	K and its analogs, thrombin, hemostatic sponge, fibrinogen).	
	Fibrinolysis inhibitors (aminocaproic acid). Drugs for stopping bleeding in patients with hemophilia (factor VIII cryoprecipitate,	
	antihemophilic plasma, coagulation factor VII, coagulation	
	factor IX). Ethamsylate. Classification. Pharmacodynamics of	
	the drug group, mechanism of action. Pharmacodynamics of	
	parameters of the drug group. Indications. Contraindications	
	Adverse reactions. Drug interactions. Use in special categories	
	of patients.	
	4.2. Drugs affecting the hematopoietic system.	Lw, Lc
	Iron preparations. Erythropoietin. Preparations containing folic	Lw, LC
	acid, cyanocobalamin.	
	Classification. Pharmacodynamics of the drug group,	
	mechanism of action. Pharmacodynamics of the drug group,	
	group. Indications. Contraindications Adverse reactions. Drug	
	interaction. Use in special categories of patients.	
Module 5.	5.1. Drugs affecting the functions of the respiratory system	Lw, Lc
Pharmacolo	Beta-2 adreno-agonists: salbutamol, fenoterol, salmeterol,	L''', L'C
gy of drugs	formoterol. M-anticholinergics: ipratropium bromide,	
groups.	tiotropium bromide. Methylxanthines: theophylline,	
Drugs	aminophylline. Mast cell membrane stabilizers (cromoglicic	
affecting the	acid), antileukotriene drugs (zafirlukast, montelukast, zileuton).	
functions of		
the	mucoregulators, mucokinetics. Antitussive drugs of central	
respiratory	action.	
system,	Classification. Pharmacodynamics of the drug group,	
digestion	mechanism of action. Pharmacokinetic parameters of the drug	
and	group. Indications. Contraindications Adverse reactions. Drug	
metabolic	interaction. Use in special categories of patients. Receptor	
processes	desensitization syndrome (tachyphylaxis, internalization and	
r		

decreased regulation - the development of resistance to beta-	
adreno-agonists), methods of its correction and prevention.	
5.2. Drugs affecting the functions of the digestive system.	Lw, Lc
Pharmacology of antacids (sodium bicarbonate, calcium	
carbonate, aluminum hydroxide, aluminum phosphate,	
magnesium oxide, magnesium hydroxide).	
Pharmacology of H2-histamine receptor blockers (cimetidine,	
ranitidine, famotidine, nizatidine, roxatidine).	
Pharmacology of M-anticholinergics: pirenzepine.	
Pharmacology of proton pump blockers (omeprazole,	
esomeprazole, lansoprazole, pantoprazole, rabeprazole).	
Pharmacology of prokinetics (metoclopramide, domperidone,	
trimebutine).	
Pharmacology of gastrocytoprotectors (bismuth, bismuth	
colloidal subcitrate, misoprostol, sucralfate).	
Tactics of prescribing antisecretory agents and prokinetics for	
the treatment and prevention of GERD, functional dyspepsia,	
NSAID gastropathy.	
Antibacterial (anti-Helicobacter) drugs in the treatment of peptic	
ulcer: amoxicillin, clarithromycin, tetracycline, metronidazole.	
Principles of eradication therapy: indications for eradication,	
basic therapy regimens, methods of monitoring the effectiveness	
of treatment.	

5.3. Hormones of the pituitary gland, hypothalamus, pineal gland, thyroid and panerous hypoglycomic drugs	Lw, Lc
gland, thyroid and pancreas, hypoglycemic drugs.	
Antidiabetic drugs: insulins (ultrashort, short, medium duration,	
long-acting), sulfonylurea derivatives (glibenclamide), glinides	
(repaglinide), biguanides (metformin), $\alpha$ -glycosidase inhibitors	
(acarbose), thiazolidindiones, dipeptidyl-peptidase-4 inhibitors	
(DPP-4) (vildagliptin), GLP-1 analogs and agonists (liraglutide),	
amylin analogs (pramlintide acetate), gliflozins (SGLT2	
inhibitors).	
Thyroid hormone preparations and antithyroid drugs (L-	
thyroxine, mercazolil, thiamazole, potassium iodide).	
Preparations of hormones of the pituitary gland and	
hypothalamus.	
Classification. Pharmacodynamics of the drug group,	
mechanism of action. Pharmacokinetic parameters of the drug	
group. Indications. Contraindications Adverse reactions. Drug	
interaction. Use in special categories of patients. Principles of	
substitution therapy.	
5.4. Hormonal preparations of steroid structure	Lw, Lc
	Lw, Lt
Sex steroids. Contraceptives. Anabolic drugs. Glucocorticoids.	
Classification. Pharmacodynamics of the drug group,	
mechanism of action. Pharmacokinetic parameters of the drug	
group. Indications. Contraindications Adverse reactions. Drug	
interaction. Use in special categories of patients. Principles of	-
substitution therapy.	Lw
<b>5.5.</b> Drugs affecting immune processes.	
I. Cytostatics:	
a) alkylating agents: cyclophosphamide	
b) antimetabolites: azathioprine methotrexate	
Glucocorticoids: prednisone, etc.	
Drugs that inhibit the formation or action of IL-2:	
a) antibiotics: cyclosporine	
tacrolimus, rapamycin	
b) MAT preparations for IL-2 receptors:	
basiliximab, daclizumab.	
Antibody preparations:	
a) Polyclonal antibodies - anti-thymocyte immunoglobulin	
b) MAT to TNF-alpha - infliximab etc.	
4-aminoquinoline derivatives (chloroquine,	
hydroxychloroquine),	
D-penicillamine,	
±	
Gold preparations (sodium aurothiomalate, auranofin, etc.).	
Classification. Pharmacodynamics of the drug group,	
mechanism of action. Pharmacokinetic parameters of the drug	
group. Indications. Contraindications Adverse reactions. Drug	
interaction. Use in special categories of patients.	
II. Immunostimulants.	
Preparations of bacterial and fungal origin, their synthetic and	
semi-synthetic analogs.	
Preparations of animal origin.	
Preparations of animal origin.	

Cytokines (interferons, interleukins) and stimulators of their	
formation in the body.	
Herbal preparations. Classification. Pharmacodynamics of the	
drug group, mechanism of action. Pharmacokinetic parameters	
of the drug group. Indications. Contraindications Adverse	
reactions. Drug interaction. Use in special categories of patients.	Lw
5.6. Antiallergic drugs	
Types of allergic reactions. Pathogenesis of allergic and pseudo-	
allergic reactions. Points of application of drugs.	
Drugs for the treatment of immediate-type hypersensitivity	
reactions:	
1) agents that prevent the release of histamine and other	
mediators of allergy - glucocorticoids, cromoglicic acid	
(cromolyn sodium);	
2) antihistamines - H1-histamine blockers;	
3) symptomatic agents - adrenergic agonists (adrenaline,	
ephedrine), myotropic bronchodilators (aminophylline).	
Drugs for the treatment of delayed-type hypersensitivity	
reactions: GCS, cytostatics.	
Classification. Pharmacodynamics of the drug group,	
mechanism of action. Pharmacokinetic parameters of the drug	
group. Indications. Contraindications Adverse reactions. Drug	
interaction. Use in special categories of patients.	

Module 6.	6.1. <b>Preparations for inhalation and intravenous</b>	Lw, Lc	
Pharmacolo	anesthesia. Analgesics	,	
gy of drugs	Opioid analgesics. Non-steroidal anti-inflammatory drugs		
groups.	(NSAIDs). Classification. Pharmacodynamics of the drug group,		
Drugs	mechanism of action. Pharmacokinetic parameters of the drug		
affecting the	group. Indications. Contraindications Adverse reactions. Drug		
central	interaction. Use in special categories of patients.		
nervous	6.2. Sedative drugs, hypnotic drugs. Antiepileptic drugs.		
system.	Classification. Pharmacodynamics of the drug group,		
Medicines	mechanism of action. Pharmacokinetic parameters of the drug		
affecting the	group. Indications. Contraindications Adverse reactions. Drug		
nociceptive	interaction. Use in special categories of patients.		
system and	6.3. Antipsychotics. Antidepressants. Drugs for the		
the synthesis	treatment of manias.		
of pain and	Classification. Pharmacodynamics of the drug group,		
inflammatio	mechanism of action. Pharmacokinetic parameters of the drug		
n mediators	group. Indications. Contraindications Adverse reactions. Drug		
n meutators	interaction. Use in special categories of patients.		
	6.4. <b>Psychostimulants. Nootropics (piracetam). Drugs for</b>		
	neurodegenerative diseases.		
	Classification. Pharmacodynamics of the drug group,		
	mechanism of action. Pharmacokinetic parameters of the drug		
	group. Indications. Contraindications Adverse reactions. Drug		
	interaction. Use in special categories of patients.		
Module 7.	7.1. Antibiotics of natural origin and semisynthetic	Lw Lc	
Pharmacolo	agents.	L., L.	
gy of drugs	The main clinically significant pathogens. Mechanisms of		
groups.	resistance. General features of antimicrobial drugs. Types of		
Antibacteria	antimicrobial pharmacotherapy. Principles of antimicrobial		
l, antiviral	therapy. Classification of antibiotics and their mechanisms of		
and	action.		
antifungal	Beta-lactam antibiotics. Pharmacology of penicillins.		
medicines	Pharmacology of cephalosporins (1st generation: cefazolin,		
methes	cephalexin, cefaclor; 2nd generation: cefamandol, cefuroxime;		
	3rd generation: cefoperazone, cefotaxime, ceftriaxone; 4th		
	generation: cefepime, 5th generation: ceftobiprole).		
	Pharmacology of carbapenems (imipenem, meropenem) and		
	monobactams (aztreonam).		
	7.2. Non-beta-lactam antibiotics and synthetic antimicrobial		
	agents:		
	Non-beta-lactam antibiotics. Pharmacology of aminoglycosides		
	(gentamicin, amikacin, tobramycin, netilmicin). Pharmacology		
	of macrolides (erythromycin, roxithromycin, azithromycin,		
	clarithromycin). Pharmacology of tetracyclines (tetracycline,		
	doxycycline) and glycopeptides (vancomycin, teicoplanin) and		
	amphenicols.		
	New groups of antibiotics: oxazolidinediones (linezolid),		
	lipopeptides (daptomycin), glycylcyclines (tigecycline),		
	pleuromutilins (retapamulin).		
	Sulfonamides, derivatives of quinolone and fluoroquinolone,	Lw, Lc	
	derivatives of 5-nitrofuran, imidazole. Classification.	,	
	Pharmacodynamics of the drug group, mechanism of action.		

	<b></b>
Pharmacokinetic parameters of the drug group. Indications.	
Contraindications Adverse reactions. Drug interaction. Use in	
special categories of patients.	
7.3. Antiviral, antifungal agents.	
Antifungal: amphotericin B, itraconazole, ketoconazole,	Lw, Lc
clotrimazole, nystatin, sertaconazole, fluconazole. Antiviral:	
anti-herpetic, anti-cytomegalovirus, anti-influenza (M2 channel	
blockers, neuroaminidase inhibitors), antiretroviral drugs, agent	
against SARS-CoV-2. Classification. Pharmacodynamics of the	
drug group, mechanism of action. Pharmacokinetic parameters	
of the drug group. Indications. Contraindications Adverse	
reactions. Drug interaction. Use in special categories of patients.	
7.4. Anti-tuberculosis drugs.	
1st line drugs, 2nd line drugs, 3 <sup>rd</sup> line drugs Anti-tuberculosis	
chemotherapy regimens. Classification. Pharmacodynamics of	Lw, Lc
the drug group, mechanism of action. Pharmacokinetic	,
parameters of the drug group. Indications. Contraindications	
Adverse reactions. Drug interaction. Use in special categories of	
patients.	
<b>7.5.</b> Antiprotozoal, anti-syphilitic, anthelmintic drugs and	
nematicides	Lw, Lc
Classification. Pharmacodynamics of the drug group,	
mechanism of action. Pharmacokinetic parameters of the drug	
group. Indications. Contraindications Adverse reactions. Drug	
interaction. Use in special categories of patients.	
* to be filled in only for <b>full</b> time training: IC lactures: IW lab work: S seminars	

\* - to be filled in only for **<u>full</u>**-time training: *LC* - *lectures; LW* - *lab work; S* - *seminars.* 

# 6. CLASSROOM EQUIPMENT AND TECHNOLOGY SUPPORT REQUIREMENTS

		Specialised educational /
		laboratory equipment,
Type of academic		
activities	Classroom equipment	software, and materials for
uctivities		course study
		(if necessary)
Lab-work	Classroom, equipped with a set	Classroom for lectures and lab works,
	of specialized furniture;	group and individual consultations,
	whiteboard; a set of devices	current control and intermediate
	includes portable multimedia	certification.
	projector, laptop, projection	A set of specialized furniture; technical
	screen, stable wireless Internet	devices: Optoma HD36 multimedia
	connection.	projector, Lenovo IdealPad330-5ikb
	Software: Microsoft Windows,	laptop, Internet access.
	MS Office /Office 365, MS	Wall projection screen, floorboard
	Teams, Chrome (latest stable	information marker magnetic,
	release), Skype	interactive complex for testing students.
	Classrooms 349, 350, 352	
Self-studies	Classroom, equipped with a set	Classroom for lectures and lab works,
	of specialized furniture;	group and individual consultations,
	whiteboard; a set of devices	current control and intermediate
	includes portable multimedia	certification.

Table 6.1. Classroom equipment and technology support requirements

Type of academic activities	Classroom equipment	Specialised educational / laboratory equipment, software, and materials for course study (if necessary)
	projector, laptop, projection screen, stable wireless Internet connection. Software: Microsoft Windows, MS Office /Office 365, MS Teams, Chrome (latest stable release), Skype Classroom 349	A set of specialized furniture; technical devices: Optoma HD36 multimedia projector, HP250G7 laptop, Internet access. Wall projection screen, floorboard information marker magnetic, interactive complex for testing students.
Learning-and Research Lab	Classroom, equipped with a set of specialized furniture; whiteboard; a set of devices includes portable multimedia projector, laptop, projection screen, stable wireless Internet connection. Software: Microsoft Windows, MS Office /Office 365, MS Teams, Chrome (latest stable release), Skype Lab No 1 on the base of the city hospital 24	Wall projection screen, magnetic floor information marker board, Optoma HD36 multimedia projector, Lenovo 15.6 laptop, centrifuge 5804, analytical scale AF225DPCT, Vortekx shaker, CryoCubeF101h freezer

\* The premises for students' self-studies are subject to <u>MANDATORY</u> mention

## 7. RESOURCES RECOMMENDED FOR COURSE STUDY

#### Main readings:

1. Illustrated textbook / editor R.N. Alyautdin. - Электронные текстовые данные. - Moscow : GEOTAR-Media, 2020. - 312 р. - Книга на английском языке. - ISBN 978-5-9704-5665-1.

#### Additional readings:

1. Tutorial Guide to Pharmacokinetics: учебное пособие / С.К. Зырянов, О.И. Бутранова, М.Б. Кубаева. – Москва: РУДН, 2022. – 134 с.: ил. ISBN 978-5-209-10837-5

2. Tutorial Guide to Pharmacodynamics [Текст] = Пособие по фармакологии : Учебное пособие / S.K. Zyryanov, O.I. Butranova. - Книга на английском языке. - М. : PFUR, 2019. - 56 с. : ил.

3. Basic and Clinical Pharmacology / B. Katzung, S. Masters. - 11th ed. ; Книга на английском языке. - New York : McGraw-Hill, 2009. - 1218 p. : il. - (LANGE Basic Science). - ISBN 978-007-127118-9 : 4318.03.

4. Clinical Pharmacology / P.N. Bennett, M.J. Brown. - 10th ed. ; Книга на английском языке. - Edinburgh : Churchill Livingstone, 2008. - 694 p. : il. - ISBN 978-0-443-10245-5 : 2048.65.

#### Internet (based) sources

**1. Electronic libraries with access for RUDN students:** -Electronic library network of RUDN – ELN RUDN http://lib.rudn.ru/MegaPro/Web - ELN «University Library online» http://www.biblioclub.ru

- ELN Urait http://www.biblio-online.ru

- ELN «Student Advisor» www.studentlibrary.ru

- ELN «Lan» http://e.lanbook.com/

#### 2. Databases and search engines:

- electronic fund of legal and regulatory and technical documentation http://docs.cntd.ru/

- search system Yandex https://www.yandex.ru/

- search system Google https://www.google.ru/

- abstract database SCOPUS http://www.elsevierscience.ru/products/scopus/

Training toolkit for self- studies to master the course \*:

1. The set of lectures on the course "Pharmacology".

2. The laboratory workshop (if any) on the course "Pharmacology".

3. The guidelines for writing a course paper / project (if any) on the course "Pharmacology".

\* The training toolkit for self- studies to master the course is placed on the course page in the university telecommunication training and information system under the set procedure.

#### ASSESSMENT 8. TOOLKIT AND GRADING SYSTEM\* FOR EVALUATION OF STUDENTS' COMPETENCES LEVEL UPON COURSE **COMPLETION**

The assessment toolkit and the grading system\* to evaluate the competences formation level (: UC-3, GPC-5, GPC-13, PC-6) upon the course study completion are specified in the Appendix to the course syllabus.

\* The assessment toolkit and the grading system are formed on the basis of the requirements of the relevant local normative act of RUDN University (regulations / order).

#### **DEVELOPERS:**

prof. of Assoc. the Department of General and Clinical O.I. Butranova Pharmacology position, department signature name and surname Head of Department of General and Clinical S.K. Zyryanov Pharmacology position, department name and surname signature HEAD OF EDUCATIONAL DEPARTMENT: of General and Clinical S.K. Zyryanov

Pharmacology

# General and Clinical

Pharmacology

name of department signature

name and surname

#### HEAD

# OF HIGHER EDUCATION PROGRAMME:

Deputy director of Institute of

Medicine fin the field of

Dentistry

position, department

signature

S.N. Razumova

name and surname